BLAINJECTIONINJECTABLEPriority Review
Approved
Jul 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
TREMFYA (guselkumab) by Johnson & Johnson is interleukin-23 antagonists [moa]. Approved for interleukin-23 antagonist [epc]. First approved in 2017.
Drug data last refreshed 2m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TREMFYA (guselkumab) is a monoclonal antibody that selectively blocks interleukin-23 (IL-23), a key cytokine in immune-mediated inflammatory diseases. It is indicated for plaque psoriasis, psoriatic arthritis, and Crohn's disease. By inhibiting IL-23 signaling, guselkumab reduces pathogenic T-cell responses and inflammation.
$0.531BPart D
PeakTREMFYA is in peak lifecycle with $531M in Part D spending; commercial teams are optimizing market position amid competitive IL-23 class saturation.
Mechanism of Action
Interleukin-23 Antagonists
Pharmacologic Class:
Interleukin-23 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study of Guselkumab in Participants With Crohn's Disease and Ulcerative Colitis
Started Jun 2026
35 enrolled
Crohn DiseaseColitis, Ulcerative
Guselkumab for Overlap Inflammatory Bowel Disease and Spondyloarthritis
Started May 2026
75 enrolled
SpondyloarthritisInflammatory Bowel Diseases
A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in Romania
Started May 2026
200 enrolled
Psoriasis
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Started Apr 2026
530 enrolled
Crohn Disease
A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Participants
Started Apr 2026
200 enrolled
Arthritis, Psoriatic
Worked on TREMFYA at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.